Naranbhai et al.
2022
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer: the CANVAX cohort study
Hauser et al.
2021
Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis
Simpson et al.
2023
Efficacy and safety of lebrikizumab in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (ADhere)
Vieujean et al.
2025
Understanding the therapeutic toolkit for inflammatory bowel disease
Wood et al.
2022
Protocol design and synopsis: omalizumab as monotherapy and as adjunct therapy to multiallergen OIT in children and adults with food allergy (OUtMATCH)
Carrascosa et al.
2014
Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies
Johns et al.
2021
Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
TWI860531B
(zh )
2024-11-01
用於預測細胞激素釋放症候群之多變量模型
Hariprasad et al.
2022
An introduction to biosimilars for the treatment of retinal diseases: a narrative review
Lin et al.
2005
Successful treatment of recalcitrant pemphigus vulgaris and pemphigus vegetans with etanercept and carbon dioxide laser
Kearns et al.
2023
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab
JP2021503476A
(ja )
2021-02-12
Ｉｌ−１７アンタゴニストを用いて化膿性汗腺炎を治療すること
Cubberley et al.
2025
Global RA treatment recommendations: An update from the various international societies
Xie et al.
2019
Sustained clinical remission of rheumatoid arthritis and its predictive factors in an unselected adult Chinese population from 2009 to 2018
Bresciani et al.
2023
Caspr1 antibodies autoimmune paranodopathy with severe tetraparesis: potential relevance of antibody titers in monitoring treatment response
Sun et al.
2021
Vedolizumab concentrations in breast milk: results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease
Paltiel et al.
2008
Immediate type I hypersensitivity response implicated in worsening injection site reactions to adalimumab
Zinger et al.
2024
Long-term effectiveness and safety of risankizumab in patients with Crohn’s disease
JP2024527230A5
(https= )
2025-06-09
Gulati et al.
2023
Systemic anticancer therapy and thromboembolic outcomes in hospitalized patients with cancer and COVID-19
Shi et al.
2025
Fast-acting treatment of myasthenic crisis with efgartigimod from the perspective of the Neuro intensive care unit
Wallace et al.
2023
Lowering expectations: glucocorticoid tapering among veterans with rheumatoid arthritis achieving low disease activity on stable biologic therapy
Giossi et al.
2022
Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: an exploratory case-control study in Italy
Al-Sawaf et al.
2023
Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison
Yegya-Raman et al.
2023
Utilization and factors precluding receipt of checkpoint inhibitor consolidation for stage III NSCLC in a large US academic health system